Andrey Borisovich Ryabov's research while affiliated with Federal Research and Clinical Centre of Pediatric Hematology, Oncology and Immunology and other places

Publication (1)

Article
Tamoxifen is a first targeted drug that continues to be the gold standard in treatment of estrogen receptor positive breast cancer for almost 50 years. The current review is an update of the paper published in 2012. We provide the new data on the tamoxifen targets that are the key points of signaling cascades activating cellular proliferation, whic...

Citations

... 5 Tamoxifen (TMX) is a selective oestrogen-receptor modulator used for the treatment of oestrogen receptor positive breast cancer. 6 Due to its low cost and safety profile, it is used worldwide. 7 TMX has shown additional activities other than anticancer such as antibacterial and antiviral. ...